Intercept pharmaceuticals, inc. (ICPT)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Cash flows from operating activities:
Net loss

-344,681

-309,242

-360,367

-412,830

-226,429

-283,226

-67,792

-43,643

-12,737

-15,087

Adjustments to reconcile net loss to net cash used in operating activities:
Foreign currency loss on liquidation

-

-

-

-

-

-

-

-191

0

0

Revaluation of warrants

-

-

-

-

-

170,832

28,441

24,625

-1,044

-672

Stock-based compensation

55,982

49,914

56,968

46,205

34,189

20,127

9,446

3,348

1,865

1,692

(Accretion) amortization of (discount) premium on investment debt securities

302

33

-3,429

-4,939

6,302

3,366

1,615

118

0

0

Amortization of deferred financing costs

2,130

1,542

1,417

685

-

-

-

-

-

-

Realized loss on investments

-

-8

-

-48

-

-

-

-

-

-

Loss from sale of assets

-

-

-

-

-

-

-

-

-217

0

Depreciation

3,700

4,600

4,600

3,831

1,691

443

106

201

410

479

Non-cash operating lease cost

5,388

-

-

-

-

-

-

-

-

-

Gain on lease termination

1,995

-

-

-

-

-

-

-

-

-

Loss on the disposal of fixed assets

-2,682

-1,331

-1,000

-

-

-20

-

-

-

-

Impairment of bonds

-

-

-

-

-

-

-

-

0

0

Accretion of debt discount

21,189

14,031

12,904

6,242

-

-

-

-

-

-

Changes in operating assets:
Accounts receivable

12,350

9,193

7,375

9,126

-

-

-

-

-

-

Prepaid expenses and other current assets

5,353

3,682

7,535

-4,284

7,516

3,371

1,714

387

630

-53

Inventory

1,354

3,628

1,201

2,279

-

-

-

-

-

-

Security deposits

-2,562

-7,153

-1,438

13,796

1,575

1,388

-

-

-

-

Other assets

24,665

-

-

-

-

-

-

-

-

-

Changes in operating liabilities:
Accounts payable, accrued expenses and other current liabilities

56,411

10,332

29,226

19,960

32,218

6,200

3,514

2,241

-83

-123

Operating lease liabilities

-6,767

-

-

-

-

-

-

-

-

-

Interest payable

562

-

208

7,267

-

-

-

-

0

0

Deferred revenue

-2,432

-2,022

-5,693

2,129

-1,782

-741

-1,622

-2,446

14,608

0

Long-term other liabilities

12,717

-1,807

5,578

-

-

-

-

-

-

-

Net cash (used in) operating activities

-236,613

-240,714

-265,402

-342,441

-162,902

-87,738

-28,006

-15,749

2,605

-13,657

Cash flows from investing activities:
Purchases of investment debt securities

603,014

436,071

231,107

511,521

640,709

204,344

125,825

65,940

0

0

Sales and maturities of investment debt securities

415,162

388,168

529,274

456,465

257,172

112,402

57,241

1,119

0

0

Redemptions of certificates of deposit

-

-

-

-

-

-

-

-3

3

-86

Purchases of equipment, leasehold improvements, and furniture and fixtures

1,136

167

10,392

5,079

5,935

4,643

1,629

38

62

29

Net cash provided by investing activities

-188,988

-48,070

287,775

-60,135

-389,472

-96,585

-70,214

-64,857

-66

57

Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs

227,300

261,362

-

-

558,756

183,475

61,169

108,499

0

19,690

Proceeds from issuance of common stock warrants

-

-

-

-

-

-

-

-

0

5,198

Payments of capital lease obligation

-

-

-

-

-

-

-

81

249

270

Proceeds from exercise of options, net

8,993

4,363

2,838

5,173

6,713

7,508

4,894

-

0

0

Payments for Capped Call Transactions and associated costs

-

-

-

38,364

-

-

-

-

-

-

Proceeds from issuance of 2026 Convertible Notes, net of issuance costs

223,424

-

-

447,573

-

-

-

-

-

-

Payments of employee withholding taxes related to stock-based awards

2,158

2,180

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

-

8

-

0

0

Proceeds from issuance of convertible promissory notes payable

-

-

-

-

-

-

-

-

0

0

Net cash (used in) provided by financing activities

457,519

263,545

2,838

414,382

565,469

190,983

66,072

108,418

-249

24,618

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-386

-1,526

1,127

-873

-376

-

-

-7

-6

-29

Net (decrease) increase in cash, cash equivalents and restricted cash

31,532

-26,765

26,338

10,933

12,719

6,660

-32,148

27,804

2,283

10,989

Supplemental disclosures of noncash activities:
Conversion of promissory note payable, including accrued interest of $91,250 into common shares

-

-

-

-

-

-

-

-

0

0

Issuance of 108,169 warrants for private placement agent fees

-

-

-

-

-

-

-

-

0

0

Acquisition of equipment pursuant to capital leases

-

-

-

-

-

-

-

-

0

0

Issuance of common stock for cashless warrant exchange

-

-

-

-

-

220,944

8,696

1,018

0

0

Supplemental disclosure of cash flow information:
Cash paid during the year for interest

-

-

-

-

-

-

-

4

13

25